[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"3H Pharmaceuticals Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100620214","phase-1-a-first-in-human-study-of-3h-10000-in-patients-with-unresectable-or-metastatic-solid-tumors-100620214",false,"NCT07354711","A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors","A Phase I\u002FII Study of 3H-10000 (an Anti-FGFR2b Antibody-Drug Conjugate) in Subjects With Unresectable or Metastatic Advanced Solid Tumors","Inclusion Criteria:\n\n* Subjects must be willing and able to sign the ICF and to adhere to the study visit schedule and other protocol requirements.\n* Male or female subjects aged ≥18 years at the time of signing the ICF.\n* According to RECIST v1.1, there is at least one measurable lesion.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1 point.\n* Life expectancy of ≥3 months.\n\nExclusion Criteria:\n\n* Meningeal diseases or carcinomatous meningitis.\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage every two weeks or more frequently.\n* Having received treatment with other investigational drugs within 4 weeks prior to the first dose of the study drug.\n* Any AEs induced by prior anti-tumor therapy having not resolved to Grade 1 or lower (except for alopecia or any other Grade 2 AEs assessed by the investigator as not being associated with any safety risk).\n* Any corneal or retinal disease\u002Fkeratopathy assessed by the investigator as of clinical significance, including but not limited to bullous\u002Fband keratopathy, corneal abrasion, inflammation\u002Fulceration, and keratoconjunctivitis.","ALL","18 Years",{"count":19,"type":20},170,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3H-10000 in the treatment of unresectable or metastatic solid tumors .",[27,28],"Lung Cancer","Stomach Cancer","RECRUITING","2026-01-18",{"date":32,"type":33},"2026-01-21","ACTUAL",{"date":35,"type":33},"2026-01-04",{"date":37,"type":20},"2029-01",{"name":39,"class":40},"3H Pharmaceuticals Co., Ltd.","INDUSTRY",""]